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862-1 Complete versus Incomplete Revaecularization for 
Acute Myocardial Infarction With Killip Class III or IV 
Subsets 
Masahisa Yamane. Soushin Indue, Hitoshi Yokozuka, Ashikaga Red Cross Hospital, 
Ashikaga Ci~ Japan. 
Background: Prognosis of the patients with acute myocardial infarction (AMI) complicated by 
congestive heart failure (CHF) or carcinogenic shock (CS) remains dismal in spite of wide 
spread use of thrombolytic therapy or pdmary engioplasty and constituted the vast majority of 
mortality. 
Method: Of 510 patients presented with AMI from 4/96 to 3/01, 117 consecutive patients 
developed CHF (n= 58) or CS (n=59) on admission and underwent stent-supported primary 
angiopiasty in < 24 hours of symptom onset, We randomly assigned conventional approach of 
angicplasty for the infarct.related artery only (Group A; n--31) or complete revasculadzation of 
angiopfasty including non-culpdt significant disease (Group B; n=50) for the patients with multi 
vessel disease at the discretion of the operator. Pdmary end-point was a 30-day end 6-month 
mortality rate. Clinical results were compared with those of singts-vessel disease and CHF or 
CS (Group C; n=36). An informed consent was obtained from the patient or a family member. 
Results: There were no differences between the Group A and the Group B regarding age 
(70¢10 versus 70¢9 yr, p=0.75),demographics, reparfusicn time (4.2±2.7 versus 6.1±4.9 
hours, p=0.06), reference vessel size (32±0.5 versus 3.3±0.4mm, p=0.26), vessel involve- 
merit (2.5 versus 2.4, p=0.22) and angiographic characteristics (LAD/RCA of 54/37 versus 63/ 
35%, p= n.s.), respeclbrsly. Angiogrsphic success defined by TIMI 3 flow end <50% diameter 
stenosis of the treated vessel was obtained in 77%* of the Group A, 94% of the Group B and 
91% of the Group C (*p=0.0038), Primary end-point of 30-day mortality rate was 36°/ot, 16% 
and 11%, respectively (tp<0.0001), and that of 6 month mortality rate was 50%, 20%, and 
15%, rasbectively(p=0.0047). 
Conclusion: Restoration of TIMI 3 flow of the infarct-related artery has achieved excellent long 
term prognosis for the patients with stable subsets, further progress could not he achieved 
wi~out improvements of clinical outcome in patients with CHF or CS. Our data suggested that 
strategy of complete ravascular~'.ation i multi vessel disease with CHF or CS might hold a 
greater promise on the patients with AMI, when anatomically and technically feasible,, 
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862-2 Benef ic ia l  Ef fect  of  G lycoprote in  l ib/I l ia Receptor 
Blockers in Patients Undergoing Primary PCI for 
Cardlogenic Shock 
Mauro Moscucci. David Share, Michael O'Donnell, Anthony C. DeFranco, William L. 
Meengs, Ann MaxwsU-Eward, John G. McGinnity, Kirit Patal, Eva Kline-Rogers, Diane 
Bondis, Vivian L. Clark, Dean E, Smith, Kim A. Eagle, For The Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium (BMC2), University of Michigan, Ann Arbor, 
Michigan. 
Background: Recant studies have shown a beneficial effect of Glycoprotein lib/Ilia (Gp lib/ 
Ilia) receptor blockers in patients undergoing primary PCI for acute myocardial infarction 
(AMI). However, data in patients with AMI complicated by cardiogenic shock (CS) are lim- 
ited. We evaluated the effect of Gp lib/life blockers on in-hospital outcomes in patients 
undergoing PCI for AMI complicated by CS in a large regional muiticentar database. 
Methods: Clinical and outcome data were prospectively collected between 7/1997 and 6/ 
2001 from 19,142 PCI in a consortium of 8 hospitals in Michigan, Of these, 323 pdmary 
PCI were performed in patients with AMI complicated by CS, 
Results: Gp lib/Ilia blockers and stents were used in 65.6% and 75% of patients respec- 
tiveley, while the combination Gp lib/Ilia blocker +stent was used in 55%. Administration of 
Gp lib/Ilia blockers was associated with higher frequency of TIMt 3 flow and with signifi- 
cantly lower in-hospital mortality (Table). This benefit remained after adjustment for base- 
line characteristics and for failure to cross the occlusion (Adjusted OR 0.55, 95% C.I. 0.32- 
0.96, p=0,037), Analysis limited to patients treated with stents revealed a trend toward 
lower mortality in patients who received a Gp Ith/llla blocker when compared with patients 
who did not (26,4% vs 34.4%, OR 0.7, 95% CI 0.37-1.31). 
Variable (%) Gp lib/Ilia Gp lib/Ilia p 
No (n=111) Yes (n=212) 
Age (years) 67.4±11,9 652±13.4 ns 
Female sex 42.3 35.3 ns 
Peripheral Vascular 14.4 9.9 ns 
Disease 
Craatinine >2 mg/dl 15.7 8 0.03 
3 vessel disease 45.0 34.9 ns 
2 vessel disease 23.4 27.6 ns 
Outcomes 
TIMI 2 flow 10.3 8.7 ns 
TIMI 3 Flow 67.9 83,7 <0.001 
In-hospital mortality 45.9 28.3 <0,002 
JACC March 6, 2002 
Conclusion: Administration of Gp IIb/itla blockers results in improved TIMI grade flow 
and improved survival for patients presenting with AMI complicated by CS. 
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862-3 Early Revascularlzation Is Associated With Improved 
Survival in Patients Aged >=75 Years With Acute 
Myocardial Infarction Complicated by Cardlogenic 
Shock: A Report From the SHOCK Trial Registry 
Vladimir Dzavik, Lynn A. Sleeper, Jorge Saucedo, Judith S, Hochmsn, Toronto General 
Hospital, University Health Netwo~, Toronto, Ontario, Canada, SL Luke's Roosevelt 
Hospital, New York, New York. 
Background. While showing that early revascularization within 6 hours of randomization 
(ERV) improves survival in the setting of acute myocardial infarction (AMI) complicated 
by cardiogenic shock (CS) of =75 years. A large prospective SHOCK Trial Registry was 
run concurrent o the Trial. The main aim of this analysis was to compare the in-hospital 
survival of patients enrolled in the Registry aged >=75 years who were selected for ERV 
versus those treated medically (IMS) and to determine the relative risk of death for the 2 
treatment groups in this elderly cohort. 
Methods: th-hospital mortality between patients aged >=75 selected for ERV and those 
selected for IMS was compared using Chi-square analysis and Cox modeling of survival 
time. The ERV group consisted of Registry patients aged >=75 years, revascolarized 
within 18 hours of onset of CS in order to approximate the ERV group in the SHOCK 
Trial, whtie patients undergoing a revasculadzation procedure later or never were 
included in the IMS group. 
Results: A total of 277 patients aged >=75 years with CS secondary to pump failure were 
analyzed (ERV n=44, IMS n=233) Mean age was 81 years and 47% were female. ERV 
patients were more likely to have been transferred into the SHOCK center, to be hyper- 
tensive, and to have severe systemic illness, th-hospital survival was 52% in patients 
treated with ERV and 19% in those selected for IMS (p<0.001). A crude comparison of 
in-hospital mortality for ERV vs. IMS in this eldedy cohort showed: RR 0.44 (95% CI 0.28, 
0.68, p=0.0003). Analysis for ERV vs. IMS for patients aged >=75 years in the Trial 
revealed a RR 1.41 (95% CI 0.95, 2.10, p=0.162) 
Conclusions. In contrast to the findings of the SHOCK Trial, the SHOCK Tdal Registry 
suggests that ERV is associated with improved survival in patients >=75 years of age 
with AMI complicated by CS. Appropdata clinical selection is likely contributing to these 
findings. Treatment of etdedy patients who present with CS complicating AMI should thus 
be individualized and when clinically feasible, ERV should be undertaken. 
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862-4 Outcome of  Ear ly  Revascu la r i za t ion  in E lder ly  Pef lente 
With Cardlogenic Shock in Acute Myocardial Infarction 
Abhiram Prasad, Peter B. Berger, Charanjit S. Rihal, David R. Holmes, Mayo Clinic, 
Rochester, Minnesota. 
Background: Subgroup analysis from the SHOCK trial indicated that patients with acute 
myocardial infarction (AMI) complicated by cardiogenic shock (CS) who were >75 years 
of age did not benefit from eady revascularizaticn, and may have been harmed; the mor- 
tality rate at 30 days was 75% (relative dsk of 1.41, p=0.0t). The applicability of this sub- 
set analysis from a select patient population enrolled in a randomized trial to the general 
population is unclear. 
Methods: We evaluated the outcome of all patients _>75 years of age at Mayo Clinic 
between 1991 to 2000 with CS secondary to AMI who underwent urgent psrcutaneous 
coronary intervention. 
Results: There were 61 patients with a median age of 79 years (25th and 75 percentiles 
77,81); 21% had a history of prior coronary artery bypass grafting (CABG), 98% had had 
a prior MI, 28% were diabetic, and 18% had a history of a cerebrovascular accident 
(CVA). Angiographic success (<50% residual stenosis) was achieved in 91% of lesions 
dilated. In hospital outcomes included death (44%), CABG (1.6%), and CVA (6.1%). Esti- 
mated survival 1 year following discharge (Kaplan Meier method) was 75 %. 
Conclusions: These data confirm a high early mortality among patients _> 75 years of 
age with AMI complicated by CS but suggest that the outcome may nonetheless be bet- 
ter than previously believed. Nsurologic complications are relatively common (6,1%) in 
such patients. Although mortality is high in the year following discharge, these data sug- 
gest that early revascularization may be beneficial among even eldedy patients with car- 
diogenic shock in AMI. 
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862-5 LINCS: L-NMMA in Cardiogenic Shock: Preliminary 
Results From a Prospective Randomized Study 
Gad Cotter, Edo Kaluski, Olga Milovanov, Alex Blatt, Ahmed Salah, Alberto Handler, 
Ricardo Krakover, Zvi Vered, Assaf-Harofeh Medical Center, Zerifin, israel. 
Backoround: In a pervious non-randomized feasibility study we have shown that L- 
NMMA is potentially efficient in the treatment of refractory cardiogenic shock. 
Patients and Methods: We enrolled 24 consecutive patients with refractory cardiogenic 
shock (un-augmentad systolic blood pressure<lCO mmHg during an acute coronary syn- 
drome despite treatment with maximal percutaneous revascularization, intraaortic bal- 
loon pump (IABP), high-dose IV dopamine and IV fluids for at least 1 hour accompanied 
by signs of peripheral hypoperfusion), All patients continued with conventional treatment 
and were randomized to no further treatment (n=12) or to receive L-NMMA 100 mg bolus 
and 100 mg,'hour continuous IV drip for 5 hours (n=12). 
Results: (1) Primary end point: Death at one month was 33% in the L-NMMA arm vs. 
